PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schaule, J.* ; Kroeze, S.G.C.* ; Blanck, O.* ; Stera, S.* ; Kahl, K.H.* ; Roeder, F.* ; Combs, S.E. ; Kaul, D.* ; Claes, A.* ; Schymalla, M.M.* ; Adebahr, S.* ; Eckert, F.* ; Lohaus, F.* ; Abbasi-Senger, N.* ; Henke, G.* ; Szuecs, M.* ; Geier, M.* ; Sundahl, N.* ; Buergy, D.* ; Dummer, R.* ; Guckenberger, M.*

Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy Melanoma brain metastases prognostic score.

Radiat. Oncol. 15:135 (2020)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Background Melanoma patients frequently develop brain metastases. The most widely used score to predict survival is the molGPA based on a mixed treatment of stereotactic radiotherapy (SRT) and whole brain radiotherapy (WBRT). In addition, systemic therapy was not considered. We therefore aimed to evaluate the performance of the molGPA score in patients homogeneously treated with SRT and concurrent targeted therapy or immunotherapy (TT/IT). Methods This retrospective analysis is based on an international multicenter database (TOaSTT) of melanoma patients treated with TT/IT and concurrent (<= 30 days) SRT for brain metastases between May 2011 and May 2018. Overall survival (OS) was studied using Kaplan-Meier survival curves and log-rank testing. Uni- and multivariate analysis was performed to analyze prognostic factors for OS. Results One hundred ten patients were analyzed. 61, 31 and 8% were treated with IT, TT and with a simultaneous combination, respectively. A median of two brain metastases were treated per patient. After a median follow-up of 8 months, median OS was 8.4 months (0-40 months). The molGPA score was not associated with OS. Instead, cumulative brain metastases volume, timing of metastases (syn- vs. metachronous) and systemic therapy with concurrent IT vs. TT influenced OS significantly. Based on these parameters, the VTS score (volume-timing-systemic therapy) was established that stratified patients into three groups with a median OS of 5.1, 18.9 and 34.5 months, respectively (p = 0.001 and 0.03). Conclusion The molGPA score was not useful for this cohort of melanoma patients undergoing local therapy for brain metastases taking into account systemic TT/IT. For these patients, we propose a prognostic VTS score, which needs to be validated prospectively.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
2.817
1.167
1
4
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Molgpa ; Melanoma ; Stereotactic ; Brain Metastases ; Immunotherapy ; Targeted Therapy; Recursive Partitioning Analysis; Radiation-therapy; Open-label; Radiosurgery; Ipilimumab; Multicenter; Diagnosis; Indexes
Language english
Publication Year 2020
HGF-reported in Year 2020
ISSN (print) / ISBN 1748-717X
e-ISSN 1748-717X
Journal Radiation Oncology
Quellenangaben Volume: 15, Issue: 1, Pages: , Article Number: 135 Supplement: ,
Publisher BioMed Central
Publishing Place Campus, 4 Crinan St, London N1 9xw, England
Reviewing status Peer reviewed
Institute(s) Institute of Radiation Medicine (IRM)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Radiation Sciences
PSP Element(s) G-501300-001
DOI 10.1186/s13014-020-01558-8
WOS ID WOS:000538061700003
Scopus ID 85085908551
PubMed ID 32487100
Erfassungsdatum 2020-06-05
[➜Report correction]